A leader in ctDNA testing was interested in investigating the opportunity for their assay to support treatment decision-making in 2 tumor types of interest (including 6 cancer subtypes)
Secondary Research
- Used NCCN guidelines to create graphics that depict the current treatment flows/regimens for patients with our 2 cancer types of interest, including details at the level of stage and prior lines of therapy; Compiled clinical literature investigating the utility of MRD testing in cancers of interest
Primary Research
- Conducted 30 in-depth interviews with oncologists / specialists who regularly treat cancer patients of interest and can speak to unmet needs in treatment decision-making; included a mix of participants from academic and community sites and varying levels of familiarity with ctDNA testing; interviews involved a high level of technical detail regarding cancer treatment workflows and therapeutic options
Quantitative Analysis
- Categorized all interviewees into 4 personas/buckets related to their readiness of adoption (based on familiarity with technology and degree of evidentiary requirements) to approximate the size of the early adopters market
30
Stakeholders Interviewed
6
Cancer Subtypes Evaluated for Opportunities
7
Applications / Opportunities Identified
DeciBio
- identified 7 opportunities across the 2 cancers of interest and ranked the opportunities based on a combined consideration of market opportunity, clinical unmet need, and ease of satisfying evidentiary requirements
- gathered interviewee feedback on several relevant clinical trial publications and presented interviewee-proposed trials that would address gaps in existing evidence
- proposed stepwise strategies for each cancer of interest, including opportunities to synergize with existing product offerings and physician channels
